Patent ID: 7169392

Claim:
A substantially homogenous sized Neisseria meningitidis serogroup B capsular oligosaccharide (MenB OS)/CRM 197 toxoid glycoconjugate produced by a method comprising: (a) providing a heterogenous population of MenB OS in which sialic acid residue N-acetyl groups are replaced with saturated N-propionyl groups; (b) obtaining a substantially homogenous sized group of MenB OS from the population of step (a) wherein said MenB OS have an average degree of polymerization (Dp) of about 12 to 18; (c) covalently attaching a C3–C16 long-chain aliphatic lipid to the nonreducing end of the MenB OS obtained in step (b); (d) introducing a reactive group at the reducing end of the MenB OS obtained in step (b) to provide single end-activated MenB OS of said DP; and (e) covalently attaching the single end-activated MenB OS obtained in step (d) to a CRM 197 toxoid carrier molecule to provide the substantially homogenous sized MenB OS/CRM 197 toxoid glycoconjugate.